Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

GSK announced that its investigational antibody-drug conjugate, risvutatug rezetecan (Ris-Rez), has received orphan drug designation in Japan for treating small-cell lung cancer...

March 23, 2026

Cybersecurity moves to the front line of healthcare operations

Cybersecurity is becoming a central factor in how healthcare organisations manage risk and maintain operational stability...

March 19, 2026

Aptamer expands pipeline with targeted radiopharmaceutical initiative

Aptamer Group is developing a proprietary radiopharmaceutical pipeline using its Optimer® platform, supported by a partnership with Radiopharmium Ltd and early data indicating improved radioligand stability compared to existing approaches...

March 18, 2026

Verici Dx highlights patient perspective in transplant care

A patient-led discussion highlights how Verici Dx is linking its diagnostics to real-world transplant care...

March 17, 2026

EU approves AstraZeneca’s Imfinzi with FLOT chemotherapy for early gastric cancer

AstraZeneca’s immunotherapy Imfinzi has been approved in the EU as part of a perioperative regimen with FLOT chemotherapy for resectable gastric and gastroesophageal junction cancers, supported by Phase III MATTERHORN..

March 16, 2026

Brava Health builds for the next phase of health and wellness

Brava Health is building tools that shift healthcare from access to proactive health optimisation...

March 13, 2026

Clarava targets pre-transplant risk in kidney rejection

A blood test designed to assess the likelihood of kidney transplant rejection before surgery so clinicians can tailor patient management...

March 11, 2026

Nuformix raises £1.0m through share placing to advance NXP002 programme

Nuformix plc has raised £1.0 million via a placing of 500 million new shares at 0.20p each. The proceeds will support additional pre-clinical studies and further development of its inhaled..

March 11, 2026

Why structure defines surgical mastery

A surgeon argues that refining structure and fundamentals, rather than chasing speed, leads to more efficient and reliable surgical outcomes...

March 10, 2026

Nuformix receives FDA Orphan Drug status for NXP002 IPF programme

The FDA has granted Orphan Drug Designation to tranilast lystate, the active compound in Nuformix’s NXP002 programme targeting idiopathic pulmonary fibrosis, a rare lung disease affecting fewer than 200,000 people..

March 10, 2026

GSK signs global licensing deal with Alfasigma for Linerixibat

GSK has entered a licensing agreement granting Alfasigma worldwide rights to develop and commercialise linerixibat, a late-stage treatment candidate for cholestatic pruritus in primary biliary cholangitis currently under regulatory review...

March 9, 2026

Changing donor pathways expand US organ availability

A growing reliance on circulatory death donation is reshaping US transplantation and strengthening demand for advanced preservation technology...

March 4, 2026

Extending surgical expertise beyond the operating theatre

Brava is building a framework to capture retiring surgeons’ clinical judgement and convert it into durable digital infrastructure that supports continuity, training and long term healthcare resilience...

March 4, 2026

Oxford Biomedica schedules Capital Markets Day and upcoming Investor Conferences

Oxford Biomedica plc will hold its Capital Markets Day on 2 June 2026 in London and participate in several investor conferences between March and June 2026. The company will also..

March 3, 2026

Oxford Nanopore reports 24% revenue growth in FY2025, reaffirms path to EBITDA breakeven

Oxford Nanopore Technologies plc (LON:ONT), the company behind a new generation of molecular sensing technology based on nanopores, has announced its preliminary results for the year ended 31 December 2025...

March 2, 2026

Smith & Nephew delivers higher profits and cash generation in 2025

Smith+Nephew reported full-year 2025 revenue of $6.16 billion, up 6.1% on a reported basis, with trading profit rising 15.5% and free cash flow increasing 52.5%...

March 2, 2026

Physicians Capital Signs Non-Binding Exclusive LOI for Acquisition by PCMC

Public Company Management Corporation (OTC:PCMC) announced it has entered into a non-binding letter of intent with Physicians Capital Management Corporation and its controlling shareholder, Conrad Ivie, M.D., regarding a potential..

February 27, 2026

Hikma Pharmaceuticals delivers 2025 revenue growth in line with guidance

Hikma achieved 6% core revenue growth and maintained resilient margins in 2025, supported by strong Branded and Hikma Rx performance. The company outlined a cautious 2026 outlook, leadership changes, a..

February 26, 2026

News and Interview Alerts

Company Presentations

Poolbeg Pharma A Strategic Vision, Pioneering the Future of Innovative Medicine

Cerillion plc Overview and Annual Results by CEO & CFO

Likewise Group Tony Brewer: Capturing beyond 10% of £2 billion flooring market (Video)

East Imperial Plc 2023 interims and strategic plans by Tony Burt, CEO

Q&As

Ilika’s Graeme Purdy on first commercial Stereax electrode delivery (LON:IKA)

14 March 2026

Hardman & Co

ICG Enterprise Trust FY’26 results: look to future realisations

11 June 2026

NB Private Equity Partners 2025 results: Looking to future realisations

29 May 2026

Chesnara Plc: Showing good operational progress

17 April 2026

Arbuthnot Banking Group Plc: 2025 lower margins, 2026 profit stability

1 April 2026

Green News

Quadrise reports progress on Valkor pilot deployment in Utah

12 June 2026

Thor Energy reports elevated hydrogen results at HY-Range project

9 June 2026

Drax agrees £548m cash acquisition of Bluefield Solar Income Fund

1 June 2026

Drax completes commissioning of Hirwaun Power Station

29 May 2026

View all Sustainable sectors, Plcs and news >>

Search

Latest Interviews

Real Estate Credit Investments: 10% Yield Strategy Backed by Senior Secured Property Lending (Video)

BrokerTalk

Likewise Group FY25 Results Highlight Ongoing Growth Momentum, Zeus

29 April 2026

Verici Dx Shows Strong Momentum with Impressive Q1 Growth, Singer Capital Markets

28 April 2026

Record’s Inflows Reinforce Confidence in Growth Pipeline

27 April 2026

Cora Gold Funding Deal Takes Sanankoro to Fully Funded Status, Says Hannam & Partners

24 April 2026

Funds

Diverse Income Trust: UK equity outlook and reconstruction proposal (LON:DIVI)

11 June 2026

Biotech Growth Trust reports strong one-year performance

11 June 2026

Ruffer Investment Company delivers positive year-to-date gains

11 June 2026

Finsbury Growth & Income Trust highlights portfolio value in May

9 June 2026

GSK to acquire Biotech Growth Trust portfolio company Nuvalent for $10.6bn

9 June 2026

View all Funds, Market Insights and news >>

FTSE 100 News

AstraZeneca’s Imfinzi plus BCG approved by FDA for high-risk bladder cancer

29 May 2026

Scottish Mortgage Investment Trust reports strong annual returns

27 May 2026

Kingfisher confirms full-year guidance after resilient Q1

26 May 2026

Melrose Industries’ GKN Garden Grove MMA tank incident update

26 May 2026

UK Broker Ratings

Goodwin PLC (GDWN.L) Stock Analysis: A Hidden Gem in Specialty Industrial Machinery with Robust Revenue Growth

9 June 2026

FirstGroup PLC (FGP.L) Stock Analysis: Examining a Potential 50% Upside for Investors

9 June 2026

Chemring Group PLC (CHG.L) Stock Analysis: Aerospace & Defense Player with a 22% Upside Potential

9 June 2026

Hilton Food Group PLC (HFG.L) Stock Analysis: Uncovering a 34.97% Potential Upside in the Packaged Foods Sector

9 June 2026

ABERDEEN GROUP PLC (ABDN.L) Stock Analysis: Navigating the Investment Landscape with a 6.12% Dividend Yield

9 June 2026

Health

Genflow Biosciences Secures £800k Funding and €4m Grant to Advance Gene Therapy Programme

Genflow Biosciences (LON:GENF) has secured fresh funding and grant support to accelerate its gene therapy research, highlighting growing momentum in the longevity biotech space. With a blend of equity financing and non-dilutive backing, the company is advancing its mission to tackle age-related diseases at the genetic level...

March 24, 2026

Nuformix Secures US Orphan Status for NXP002 as Licensing Talks Advance (video)

Nuformix strengthens its NXP002 programme with US orphan drug designation, unlocking market exclusivity in a region accounting for the majority of IPF revenues. With fresh capital and ongoing partner discussions, the company is positioning itself to advance a differentiated inhaled therapy while negotiating from strength...

March 24, 2026

GSK’s Ris-Rez granted Orphan Drug Status in Japan for small-cell lung cancer

GSK announced that its investigational antibody-drug conjugate, risvutatug rezetecan (Ris-Rez), has received orphan drug designation in Japan for treating small-cell lung cancer...

March 23, 2026

Cybersecurity moves to the front line of healthcare operations

Cybersecurity is becoming a central factor in how healthcare organisations manage risk and maintain operational stability...

March 19, 2026

Aptamer expands pipeline with targeted radiopharmaceutical initiative

March 18, 2026

Verici Dx highlights patient perspective in transplant care

A patient-led discussion highlights how Verici Dx is linking its diagnostics to real-world transplant care...

March 17, 2026

EU approves AstraZeneca’s Imfinzi with FLOT chemotherapy for early gastric cancer

March 16, 2026

Brava Health builds for the next phase of health and wellness

Brava Health is building tools that shift healthcare from access to proactive health optimisation...

March 13, 2026

Clarava targets pre-transplant risk in kidney rejection

A blood test designed to assess the likelihood of kidney transplant rejection before surgery so clinicians can tailor patient management...

March 11, 2026

Nuformix raises £1.0m through share placing to advance NXP002 programme

Nuformix plc has raised £1.0 million via a placing of 500 million new shares at 0.20p each. The proceeds will support additional pre-clinical studies and further development of its inhaled NXP002 treatment for pulmonary fibrosis...

March 11, 2026

Why structure defines surgical mastery

A surgeon argues that refining structure and fundamentals, rather than chasing speed, leads to more efficient and reliable surgical outcomes...

March 10, 2026

Nuformix receives FDA Orphan Drug status for NXP002 IPF programme

March 10, 2026

GSK signs global licensing deal with Alfasigma for Linerixibat

March 9, 2026

Changing donor pathways expand US organ availability

A growing reliance on circulatory death donation is reshaping US transplantation and strengthening demand for advanced preservation technology...

March 4, 2026

Extending surgical expertise beyond the operating theatre

March 4, 2026

Oxford Biomedica schedules Capital Markets Day and upcoming Investor Conferences

Oxford Biomedica plc will hold its Capital Markets Day on 2 June 2026 in London and participate in several investor conferences between March and June 2026. The company will also report FY 2025 preliminary results on 26 March 2026, followed by a virtual analyst briefing...

March 3, 2026

Oxford Nanopore reports 24% revenue growth in FY2025, reaffirms path to EBITDA breakeven

March 2, 2026

Smith & Nephew delivers higher profits and cash generation in 2025

Smith+Nephew reported full-year 2025 revenue of $6.16 billion, up 6.1% on a reported basis, with trading profit rising 15.5% and free cash flow increasing 52.5%...